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}iperacillin/tazobactam (ZOSYN, Lederle Labo-
ratories, Pearl River, NY) is the most recently
approved combination of a [3-1actam antimicrobial
agent with an inhibitor of bacterial [3-1actamases.
In vitro and clinical studies have demonstrated effi-
cacy in polymicrobial infections such as obstetric,
gynecologic, and soft-tissue infections. Piperacillin/
tazobactam appears to be an appropriate drug for
the empiric treatment of gynecologic infections be-
cause of its broad spectrum, good penetration of
tissues, and minimal side-effect profile. Multiple
studies have demonstrated that piperacillin/tazo-
bactam, compared with "gold standard" treatment
regimens, is an equally effective and safe alterna-
tive. It may also prove to be more cost effective,
based on early reports of broad microbiologic cover-
age and high cure rates.
STRUCTURE AND DERIVATION
Piperacillin is a semisynthetic ureidopenicillin with
an extended spectrum of activity. Piperacillin so-
dium is derived from D(-)-ot-aminobenzylpeni-
cillin. The chemical name is sodium (2S, 5R, 6R)-
6-[(R)-2-(4-ethyl-2,3-d oxo-p perazine-carboxy-
amido)-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-
thia-l-azabicyclo [3.2.1]-heptane-2-carboxylate.
Tazobactam sodium is a triazolymethyl penicil-
lanic-acid sulfone derivative. The triazole ring facil-
itates the binding of tazobactam to [3-1actamases.
The chemical name is sodium (2S, 3S, 5R)-3-
me hyl-7-oxo-3- 1H,2,3-triazol- 1-ylme hyl)-4- h a-
1-azabicyclo-[3.2.0]-heptane-2-carboxylate-4, 4-di-
oxide.
Both structures are highly water soluble, with
pKas of 2.1 and 4.14, respectively,
MECHANISM OF ACTION
All penicillins share a basic structure of a thiazoli-
dine ring connected to a 13-1actam ring with an
attached side chain. The properties of penicillin are
affected by altering the side chain, thus forming a
variety of different penicillin compounds. Penicil-
lins essentially have the same bactericidal mecha-
nism, interfering with the synthesis of the peptido-
glycan component of the cell wall. In recent years,
[3-1actam drugs have been combined with [3-1actam
inhibitors. 13-1actam inhibitors have the ability to
bind irreversibly to 13-1actamase enzymes, thereby
increasing the antimicrobial activity of several [3-
lactam antibiotics. Although tazobactam has little
intrinsic antimicrobial activity, it binds covalently
to a clinically important number of plasmids and
chromosomally mediated [3-1actamases. It has en-
hanced piperacillin’s bactericidal activity. Tazo-
bactam provides an added advantage over other [3-
lactam inhibitors in that it exhibits minimal induc-
tion of class-l, chromosomally mediated 13-1acta-
mase enzymes.
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PHARMACOKINETICS
The pharmacokinetics of piperacillin and tazobac-
tam are similar. Tazobactam and piperacillin are
highly water soluble. They bind very weakly to
plasma proteins (20-30%) after intravenous (IV) ad-
ministration. As both agents leave the intravascular
space quickly, distribution is complete within
30 rain after administration, Piperacillin and tazo-
bactam are widely distributed in tissues and thera-
peutic levels are achieved in skin, muscle, intestinal
mucosa, appendix tissue, and fatty tissue. The
peak concentrations of piperacillin and tazobactam
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in muscle, skin, and gastrointestinal mucosa occur
within 1-2 h after infusion.
Piperacillin plasma concentrations, following the
infusion of piperacillin/tazobactam, are similar to
those attained when equivalent doses of piperacillin
are administered alone. The mean peak plasma
concentrations are approximately 134, 242, and
298 Ixg/ml for 2.25-, 3.375-, and 4.5-g doses, respec-
tively. The corresponding mean peak plasma con-
centrations of tazobactam are 15.24 and 34 Ixg/ml,
respectively. The total clearance decreases slightly
with an increase in dose. The plasma half-life of
piperacillin and of tazobactam ranges from 0.7 to
1.2 h.
The amount of inhibitor that can be delivered
to the site of infection is an important determinant
of the efficacy of a drug combination. The standard
dose of piperacillin/tazobactam is 3.375 g (3 g of
piperacillin and 0.375 g of tazobactam) adminis-
tered q 6 h. After the dosing of 3 g of piperacillin
and 0.375 g oftazobactam over 5 min, the maximum
concentration (Cmax) (rag/l) is 336 with an area under
the curve (AUC) of 230; Cl,v is 219; and 51.7% is
excreted in the urine. Multiple dosing has not been
shown to affect the pharmacokinetics. Currently,
pharmacokinetic studies are addressing if the doses
of 3.375 g q 6 h and 4.5 g q 8 h are bioequivalent.
An q-8-h dosing of piperacillin/tazobactam is be-
lieved to be possible based on several earlier studies
on piperacillin pharmacokinetics in normal patients.
Piperacillin is metabolized to a minimally active
desthyl metabolite that insignificantly contributes
to the overall elimination of piperacillin. Tazobac-
tam is metabolized to an essentially inactive metab-
olite (M 1).z The elimination pathways of both pip-
eracillin and tazobactam include ultrafiltration
(kidney); paracellular elimination; and renal, he-
patic, and gastrointestinal secretions. Both com-
pounds are believed to be eliminated renally by
tubular secretion and glomercular filtration; there-
fore, renal failure compromises its elimination. It
has been suggested that the dosing interval be ex-
tended to 8 h in patients with creatinine clearances
(Ccr) that range between 20 and 40 ml/min and to
10 h with Ccr of <20 ml/min,
The concomitant administration of probenecid
and piperacillin/tazobactam significantly prolongs
the 13 half-life (tl/zbota) for tazobactam and signifi-
cantly decreases the piperacillin mean CLR.
1 The
authors of this study suggested that these changes
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likely offered no therapeutic advantage or war-
ranted dosage modifications if probenecid is used
concurrently.
SAFETY PROFILE
Overall, piperacillin/tazobactam has a safety profile
similar to those of other 13-1actam/13-1actamase in-
hibitor combinations. The adverse reactions, which
are generally not severe, rarely interfere with the
continuation of therapy.
Only 3.2% of 2,261 patients studied worldwide
had adverse effects that warranted the termination
of therapy. The most common adverse experiences
related to treatment were allergic skin reactions
(1.3%) and gastrointestinal disturbances (0.9%),
most often diarrhea. Clinical comparative studies
have documented a higher incidence of diarrhea
with piperacillin/tazobactam treatment than with
other combination antibiotic therapies.
1 The most
common laboratory abnormalities have been related
to hepatic function: a 1.1% increase in total bilirubin
levels and a 5.6% increase in alanine aminotransfer-
ase levels. The incidence of elevations increased
with concurrent aminoglycoside administration.
Piperacillin/tazobactam has been classified as a
pregnancy-risk category-B drug.
SPECTRUM OF ANTIMICROBIAL
ACTIVITYEMPIRIC AND SELECTED
Two large comparative studies were performed to
evaluate piperacillin/tazobactam’s in vitro antimi-
crobial activity, lz’13 These studies demonstrated that
piperacillin/tazobactam has an excellent empiric
spectrum. This combination is highly active against
gram-positive bacteria, including strains that pro-
duce [3-1actamase, and inhibits a wide spectrum of
both fastidious and non-fastidious gram-negative
bacilli, including Pseudomonas aeruginosa. Piperacil-
lin/tazobactam also inhibits a broader spectrum of
anaerobes than does ampicillin/sulbactam or ticar-
cillin/clavulanate.
A large comparative study tested the antimicro-
bial activity of piperacillin combined with tazobac-
tam at a fixed concentration of 4 Ixg/ml and a ratio
of 8:1. A total of 5,029 clinical isolates of gram-
negative and gram-positive aerobic pathogens and
447 fastidious organisms including anaerobes from 5
medical centers were included.z The study results
were as follows: >95;% inhibition of Enterobacteria-
ceae; 93.5% inhibition for non-enteric gram-nega-
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TABLE I. In vitro activity of broad-spectrum 13-Lactams for pelvic infections s-7a
Susceptibility
Pip Amp/Sul Ticar/Clav Cftax/Cftrx Cftaz Imip Pip/Tazo
Staphylococcus aureus 0 *** *** * * *** ***
S. pyogenes *** *** *** *** *** *** ***
Enterococcus faecalis *** *** * 0 0 ** ***
Enterobacteriaceae *** * *** *** *** *** ***
Neisseria gonorrhoeae ** *** *** *** *** *** ***
Pseudomonas aeruginosa *** 0 * * *** *** ***
Bacteroides fragilis ** *** *** */0 0 *** ***
B. bivius ** *** *** 0 0 0 *** ***
aAIthough a useful guide, in vitro activity does not necessarily correlate with clinical response. Pip piperacillin; Amp/Sul- ampicillin/sulbactam;
Ticar/Clav ticarcillin/clavulanate; Cftax/Cftrx cefotaxime/ceftriaxone; Cftax cefmetazole; Imip imipenem; Pip/Tazo piperacillin;/tazobactam.
Susceptibility: 0 <50%; * 50-75%; ** 75-90%; *** >90%.
tive bacilli (the most active agent); 89.3% inhibition
against staphylococci (ampillicin/sulbactam was the
most active agent at 95%); 91% inhibifon against
enterococci; 93.5% inhibition of all aerobic isolates;
100% of all fastidious isolates tested; and 99.5%
inhibition of anaerobic isolates.
A national survey of the in vitro spectrum of
piperacillin/tazobactam at 236 medical centers also
demonstrated its wide antimicrobial activity.
13 Pi-
peracillin/tazobactam and imipenem displayed the
widest antimicrobial spectra, inhibiting >90% of all
isolates tested.
Piperacillin/tazobactam, similar to other combi-
nation regimens comprising the penicillin group,
does not cover methicillin-resistant staphylococci,
strains of enterococci that are resistant to both 13-
lactams and chromosomally mediated 13-1acta-
mases. 14 Pseudomonas spp. should be covered with
higher doses of piperacillin/tazobactam (4/0.5 g
q 6 h or 3/0.75 g q 4 h) plus an aminoglycoside.
In summary, in vitro studies have demonstrated
the broad antimicrobial activity and clinical efficacy
of piperacillin/tazobactam. Table summarizes the
in vitro activity of broad-spectrum 13-1actams in pel-
vic infections. s-7
CLINICAL APPLICATIONS
Currently, the Food and Drug Administration
(FDA) has approved piperacillin/tazobactam for the
treatment of intraabdominal infections, skin and
skin-structure infections, postpartum endometritis
or pelvic inflammatory disease (PID), and commu-
nity- and hospital-acquired pneumonia.
The majority of pelvic infections are polymicrob-
ial in nature, with mixed aerobic, facultative, and
TABLE 2. Example costs of acquisition and IV
administration of various antibiotic regimens
Antibiotic Dosing Cost/day
Ampicillin/sulbactam 3 g q 6 h $59.68
Ticarcillin/clavulanate 3.1 g q 6 h $58.96
Piperacillin/tazobactam 3.375 g q 6 h $65.27
4.5 g q 8 h $60.09
Imipenem/cilastatin 500 mg q 8 h $95.05
Cefmetazole 2 g q 8 h $51.24
Cefotaxime 2 g q 8 h $58.93
Clindamycin/gentamicin 900 mg/80 mg q 8 h $37.57
anaerobic bacteria involved. The medical literature
supports empiric treatment regimens with adequate
coverage comparable to a single-agent cephalospo-
rin or extended-spectrum penicillins with high rates
of cure. In previous studies, piperacillin alone has
been shown to be as efficacious as standard regi-
mens in the treatment of pelvic infections. 8’19
In a randomized study by Sweet et al.,z piperacil-
lin and tazobactam, 3.375 g q 6 h (N 196) was
compared with clindamycin, 900 mg, and gentami-
cin, 2.5-5.0 mg/kg/d q 8 h (N 103) in hospitalized
women with pelvic infections. A total of 87% of the
infections were either endometritis or PID. The
combination of piperacillin/tazobactam produced
favorable clinical responses in 85% of the patients
vs. 87% of the gentamicin/clindamycin-treated
group. These differences were not clinically signifi-
cant. The bacteriologic responses were comparable
in the 2 groups: 78% and 82%, respectively. Some
Streptococcus spp. were the only organisms isolated
that were resistant to piperacillin/tazobactam. The
investigators concluded that the combination of
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TABLE 3. Activity of piperacillin/tazobactam against major pathogens
Examples of organisms with MICg0
I-<lxg/ml 2-8 txg/ml 16-64 Ixg/ml
Streptococcus pyogenes
S. agalactaiae
S. pneumoniae
S. viridans
Groups C, D, F, G streptococci
Haemophilus intluenzae
Moraxella catarrhalis
Anaerobic gram-positive cocci
Staphylococcus aureus (oxacillin-susceptible)
S. aureus, coagulase-negative (oxacillin-susceptible)
Enterococcus faecalis
Klebsiella pneumoniae
K. oxytoca
Proteus mirabilis
Serratia marcescens
Bacteroides fragilis
B. non-fragilis group
Escherichia coli
Pseudomonas aeruginosa
Aeianetobacter anitratus
Enterobacter cloacae
E. aerogens
B. fragilis group
piperacillin/tazobactam is an effective, well-toler-
ated regimen.
Two non-comparative studies of piperacillin/ta-
zobactam (4/0.5 g q 8 h) for the treatment of pelvic
infections (mean duration of 5 days) are in the cur-
rent literature. Tapp et al. 21 used piperacillin/tazo-
bactam in a non-comparative study to treat 25 pa-
tients with pelvic infections. Of the 20 evaluable
patients, 95% were clinically cured. Six patients had
organisms isolated, none of which was resistant to
piperacillin or the piperacillin/tazobactam combina-
tion. Sanders22 studied patients diagnosed with pel-
vic infections (salpingitis, endometritis, tubo-ovar-
ian abscesses, cuff infections, and pelvic soft-tissue
infections). Eighty-nine patients (86%) completed
the study, of whom 66% were clinically evaluable
and 29% microbiologically evaluable. Ninety per-
cent of the patients demonstrated favorable clinical
outcomes by the study’s end point. Bacteriologic
eradication was achieved in 90% of these patients.
A direct comparison of ticarcillin/clavulanate and
piperacillin/tazobactam for the treatment of lower-
respiratory-tract infections showed piperacillin/ta-
zobactam to be clinically superior. In the treatment
of skin and soft-tissue infections, the 2 regimens
were comparable. Piperacillin/tazobactam was at
least as effective as imipenem/cilastatin and clinda-
mycin plus gentamicin for the treatment of intraab-
dominal infections, including the q-8-h dosing
regimen.
14
Piperacillin alone for prophylaxis in preterm
membrane rupture has been studied. A double-
blind, placebo-controlled trial demonstrated that
the use of IV piperacillin for 72 h in preterm prema-
ture rupture of the membranes significantly pro-
longed the latency period between membrane rup-
ture and delivery,
z3 The mean latency period was
prolonged in the piperacillin group vs. the control
group (11.4 _
18.8 vs. 6.1 __+ 13.6 days, respec-
tively; P 0.001).
COST
Although the costs for the acquisition and adminis-
tration of antibiotics vary by institution, the relative
costs are usually comparable. The costs for acquisi-
tion plus a $5.00/dose charge for IV preparation
and administration for various antibiotic regimens
commonly utilized for the treatment of obstetric
and gynecologic infections at our hospital are given
in Table 2.
Therefore, piperacillin/tazobactam appears to be
comparable to other [3-1actamase inhibitor combina-
tions and much less expensive than imipenem-cila-
statin. Although single-agent cephalosporins and
clindamycin/gentamicin are less expensive, their
enterococcal coverage is lacking. While the signifi-
cance of enterococcal coverage is still under debate,
the recent increase in vancomycin-resistant entero-
cocci is of great concern, indicating that enterococ-
cal coverage may become a factor in the selection
of empiric antibiotics in the future.
CONCLUSIONS
Piperacillin/tazobactam is an appropriate regimen
for the treatment of gynecologic infections. This
regimen covers a broad spectrum of pathogens,
thereby providing empiric coverage (Table 3). Pi-
peracillin/tazobactam has clinical and bacteriologic
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responses comparable to clindamycin/gentamicin,
demonstrating efficacy in polymicrobial infections,
good penetration of gynecologic tissues, and good
tolerance.
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